Literature DB >> 1303573

[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].

W H Jost1, U Mielke, M C Forrett-Kaminsky, K Schimrigk.   

Abstract

A patient with a 5 year history of slow-progressive Lambert-Eaton Myasthenic Syndrome (LEMS) was treated for a period of 12 months with 3,4-diaminopyridine (3,4-DAP). The therapy led to an objective increase in muscle power. During the treatment period, there was no increase in muscle weakness, but attempts at withdrawal of the drug confirmed a progression. The mouth dryness disappeared and autonomic regulation disturbances were improved. All of the laboratory parameters remained unchanged. A neoplasia was excluded by extensive endoscopic and radiological investigations. Side-effects included initial perioral paresthesia and, later, paresthesia down the skin and along the ulnar edge of the forearm. 3,4-DAP seems to be an effective and acceptable long-term symptomatic therapy in LEMS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1303573

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.

Authors:  M Strupp; R Kalla; J Claassen; C Adrion; U Mansmann; T Klopstock; T Freilinger; H Neugebauer; R Spiegel; M Dichgans; F Lehmann-Horn; K Jurkat-Rott; T Brandt; J C Jen; K Jahn
Journal:  Neurology       Date:  2011-07-06       Impact factor: 9.910

2.  3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.

Authors:  Laurent Flet; Elisabeth Polard; Olivia Guillard; Emmanuelle Leray; Hervé Allain; Loïc Javaudin; Gilles Edan
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

Review 3.  3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.

Authors:  J Molgó; J M Guglielmi
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.